Hummingbird Bioscience Appoints Jan Møller Mikkelsen As Chairman Of The Board
Hummingbird Bioscience Holdings Limited, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, announced the appointment of Jan Møller Mikkelsen as Chairman of its Board of Directors.
Recommended AI News: Top 5 NFT Collectibles Worth $10.2 Billion in November
“I am delighted to welcome Jan to Hummingbird’s Board of Directors as our Chairman. His extensive experience leading and scaling businesses spanning from drug discovery to commercial stage companies is invaluable to Hummingbird Bioscience, as we chart our next stage of growth and pursue our mission of bringing precision medicines to patients,” said Piers Ingram, CEO and co-founder of Hummingbird Bioscience.
Mr. Mikkelsen currently serves as President, CEO and Board member of Ascendis Pharma, a pharmaceutical company he founded in 2007. He was previously President and CEO of LifeCycle Pharma, President of the Pharmaceutical Division of Maxygen, Inc., as well as co-founder of ProFound Pharma where he also served as co-CEO. Prior to that, Mr. Mikkelsen held various positions at Novo Nordisk, a global healthcare company, including Vice President of Protein Discovery.
Recommended AI News: Confluence Announces Partnership With Fund Service Provider, FundHero
“I am pleased to join Hummingbird’s Board as Chairman at this pivotal time as the Company’s promising lead assets progress into clinical development. I look forward to working with Piers, the Hummingbird senior management team and the Board to maximize the therapeutic impact of the programs generated by the Company’s Rational Antibody Discovery platform, and to achieve our ambitions to generate breakthrough therapies against hard targets,” said Mr. Mikkelsen.